about
Rightward dominance in temporal high-frequency electrical asymmetry corresponds to higher resting heart rate and lower baroreflex sensitivity in a heterogeneous population.Adenylyl cyclase signaling in the developing chick heart: the deranging effect of antiarrhythmic drugsCardiac Syndrome X: update 2014.Human stem cells for modeling heart disease and for drug discovery.The hippo pathway in heart development, regeneration, and diseasesEpidemiology and management of antiretroviral-associated cardiovascular disease.The potential of stem cells in the treatment of cardiovascular diseases.Analysis of therapeutic effect and safety of target-dose metoprolol in the treatment of patients with diabetes mellitus with chronic heart failure.Clinical relevance of target identity and biology: implications for drug discovery and development.Calcium channel blockers in cardiovascular pharmacotherapy.Small molecule and peptide therapies for chronic heart failure: a patent review (2011 - 2014).Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine.Beta-Blockers and Calcium Channel Blockers: First Line Agents.Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders.Impact of neuro-psychological factors on smoking-associated lung cancer.Esmolol acutely alters oxygen supply-demand balance in exercising muscles of healthy humans.Repurposing established cyclic adenosine monophosphate reducing agents for the prevention and therapy of epidermal growth factor receptor inhibitor resistance in non-small cell lung cancer.
P2860
Q30409091-C115671B-DDA3-4EB2-8346-56A8A756EC90Q33876726-8B861C3A-C9BD-4B43-8F17-9802EB7FA4B0Q34007353-AB48BF66-01AC-47B3-A852-052E894FCD78Q34433363-C85AE156-4765-4068-9CC2-339C716AB7FFQ34470968-70BCD000-1B33-4009-9092-EB8D3C708F22Q35338096-DD71339B-2C0E-4A3A-A9D7-7AEAA4B7EADEQ37325686-614D6429-F876-4A75-B39C-CBE4F412AAB9Q37639579-EEBEFE83-6211-4D87-8826-6212D9198C69Q38147723-0FA74367-BE20-4099-9D39-73110AB8D196Q38215726-9B26F9DB-A7C6-485B-AAEC-275A3258BFE5Q38546917-D6945E9F-941A-4C18-8D76-F33EAADBCE86Q38874111-4B03110D-87CD-4177-994E-A501D7C44F69Q38941375-4D6E77B0-2C15-484B-B2A0-ABC08BB0118DQ41137764-C7125C26-3D9C-4AF0-8143-BA41145FEC8DQ44959002-FE5A99FC-355A-4C3A-9187-F3A29015E48BQ53073241-0B13798E-4EA2-4108-965C-C35216F8A46BQ54986008-94E2362F-3495-4B99-B3F0-497311A73DAD
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
β-Adrenergic blockade in cardiovascular disease.
@en
type
label
β-Adrenergic blockade in cardiovascular disease.
@en
prefLabel
β-Adrenergic blockade in cardiovascular disease.
@en
P2860
P356
P1476
β-Adrenergic blockade in cardiovascular disease.
@en
P2093
William H Frishman
P2860
P304
P356
10.1177/1074248413484986
P577
2013-04-30T00:00:00Z